REGN7075

Principal investigator

Dr. M. Vollebergh

Medication

REGN7075 (human IgG4-based Costimulatory bispecific antibody: EGFR and CD28), cemiplimab, platinum-based chemotherapy

Summary

The aim of the study is to see how safe and tolerable REGN7075 is alone and in combination with cemiplimab (with or without chemotherapy), and to find out what the best dose REGN7075 is in combination with cemiplimab (with or without chemotherapy). Another goal is to see how effective REGN7075 is alone, or in combination with cemiplimab (with or without chemotherapy). The research consists of 2 parts. The purpose of Part 1 is to find the highest and safe dose of REGN7075 that can be combined with a standard dose of cemiplimab. In Part 2, the dose and schedule selected in Part 1 will be further investigated in additional patients to gather more information about the safety and efficacy of this dose. In Part 2, depending on the type of cancer, chemotherapy can be combined with REGN7075 and cemiplimab.

Read more on clinicaltrials.gov.

Notes

• CRC, Squamous Cell Carcinoma of the Skin, NSCLC – Open